Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361812258> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4361812258 abstract "<div>AbstractPurpose:<p>In this study, we aimed to evaluate the efficacy and safety of pyrotinib, a pan-HER inhibitor, in patients with <i>HER2</i>-amplified non–small cell lung cancer (NSCLC).</p>Patients and Methods:<p>In this prospective, multicenter, single-arm trial (ChiCTR1800020262), patients with advanced NSCLC with <i>HER2</i> amplification, as determined by next-generation sequencing, were enrolled and administered pyrotinib orally at 400 mg per day. The primary endpoint was 6-month progression-free survival (PFS) rate. Other endpoints included objective response rate (ORR), disease control rate (DCR), PFS, overall survival (OS), and safety.</p>Results:<p>The enrolled cohort included 27 patients with <i>HER2</i> amplification. The 6-month PFS rate was 51.9% [95% confidence interval (CI), 34.0–69.3]. The median PFS (mPFS) was 6.3 months (95% CI, 3.0–9.6 months), and median OS was 12.5 months (95% CI, 8.2–16.8 months). Pyrotinib elicited a confirmed ORR of 22.2% (95% CI, 10.6%−40.8%). Patients administered pyrotinib as first-line treatment achieved an mPFS of 12.4 months. Moreover, 30.8% of the patients who had progressed on EGFR tyrosine kinase inhibitor (TKI) responded to pyrotinib. Patients with brain metastases had an ORR of 40%. Treatment-related adverse events (TRAE) occurred in all patients (grade 3, 22.2%), but no grade 4 or higher TRAEs were documented. Diarrhea was the most frequent TRAE (all, 92.6%; grade 3, 7.4%). Loss of <i>HER2</i> amplification was detected upon disease progression.</p>Conclusions:<p>Pyrotinib provided antitumor efficacy with a manageable safety profile in <i>HER2</i>-amplified patients with NSCLC.</p></div>" @default.
- W4361812258 created "2023-04-05" @default.
- W4361812258 creator A5000807789 @default.
- W4361812258 creator A5003033802 @default.
- W4361812258 creator A5004928583 @default.
- W4361812258 creator A5007646657 @default.
- W4361812258 creator A5024792434 @default.
- W4361812258 creator A5024877519 @default.
- W4361812258 creator A5026806656 @default.
- W4361812258 creator A5027351735 @default.
- W4361812258 creator A5030071648 @default.
- W4361812258 creator A5033293085 @default.
- W4361812258 creator A5047447610 @default.
- W4361812258 creator A5062758711 @default.
- W4361812258 creator A5066879163 @default.
- W4361812258 creator A5085215477 @default.
- W4361812258 creator A5088343715 @default.
- W4361812258 date "2023-03-31" @default.
- W4361812258 modified "2023-09-28" @default.
- W4361812258 title "Data from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial" @default.
- W4361812258 doi "https://doi.org/10.1158/1078-0432.c.6532401.v1" @default.
- W4361812258 hasPublicationYear "2023" @default.
- W4361812258 type Work @default.
- W4361812258 citedByCount "0" @default.
- W4361812258 crossrefType "posted-content" @default.
- W4361812258 hasAuthorship W4361812258A5000807789 @default.
- W4361812258 hasAuthorship W4361812258A5003033802 @default.
- W4361812258 hasAuthorship W4361812258A5004928583 @default.
- W4361812258 hasAuthorship W4361812258A5007646657 @default.
- W4361812258 hasAuthorship W4361812258A5024792434 @default.
- W4361812258 hasAuthorship W4361812258A5024877519 @default.
- W4361812258 hasAuthorship W4361812258A5026806656 @default.
- W4361812258 hasAuthorship W4361812258A5027351735 @default.
- W4361812258 hasAuthorship W4361812258A5030071648 @default.
- W4361812258 hasAuthorship W4361812258A5033293085 @default.
- W4361812258 hasAuthorship W4361812258A5047447610 @default.
- W4361812258 hasAuthorship W4361812258A5062758711 @default.
- W4361812258 hasAuthorship W4361812258A5066879163 @default.
- W4361812258 hasAuthorship W4361812258A5085215477 @default.
- W4361812258 hasAuthorship W4361812258A5088343715 @default.
- W4361812258 hasBestOaLocation W43618122582 @default.
- W4361812258 hasConcept C126322002 @default.
- W4361812258 hasConcept C143998085 @default.
- W4361812258 hasConcept C188816634 @default.
- W4361812258 hasConcept C197934379 @default.
- W4361812258 hasConcept C203092338 @default.
- W4361812258 hasConcept C2776256026 @default.
- W4361812258 hasConcept C44249647 @default.
- W4361812258 hasConcept C535046627 @default.
- W4361812258 hasConcept C71924100 @default.
- W4361812258 hasConcept C90924648 @default.
- W4361812258 hasConceptScore W4361812258C126322002 @default.
- W4361812258 hasConceptScore W4361812258C143998085 @default.
- W4361812258 hasConceptScore W4361812258C188816634 @default.
- W4361812258 hasConceptScore W4361812258C197934379 @default.
- W4361812258 hasConceptScore W4361812258C203092338 @default.
- W4361812258 hasConceptScore W4361812258C2776256026 @default.
- W4361812258 hasConceptScore W4361812258C44249647 @default.
- W4361812258 hasConceptScore W4361812258C535046627 @default.
- W4361812258 hasConceptScore W4361812258C71924100 @default.
- W4361812258 hasConceptScore W4361812258C90924648 @default.
- W4361812258 hasLocation W43618122581 @default.
- W4361812258 hasLocation W43618122582 @default.
- W4361812258 hasOpenAccess W4361812258 @default.
- W4361812258 hasPrimaryLocation W43618122581 @default.
- W4361812258 hasRelatedWork W1608269846 @default.
- W4361812258 hasRelatedWork W2022417792 @default.
- W4361812258 hasRelatedWork W2032912323 @default.
- W4361812258 hasRelatedWork W2390152934 @default.
- W4361812258 hasRelatedWork W2518309888 @default.
- W4361812258 hasRelatedWork W2765926618 @default.
- W4361812258 hasRelatedWork W2902679640 @default.
- W4361812258 hasRelatedWork W2904759734 @default.
- W4361812258 hasRelatedWork W3089163820 @default.
- W4361812258 hasRelatedWork W4282918911 @default.
- W4361812258 isParatext "false" @default.
- W4361812258 isRetracted "false" @default.
- W4361812258 workType "article" @default.